Ready to Use. We believe that RUT58-60, if approved by the FDA, will be the only prepackaged, sterilized, ready-to-use hypochlorous acid based drug designed to prevent infection following surgery. We intend to package RUT58-60 in convenient, sterile packaging that will not require mixing or solution preparation prior to use, thereby reducing the need for human intervention and further minimizing opportunities to introduce other organisms that may cause infection and the risk of medical error.
Appears in 4 contracts
Sources: License and Supply Agreement (Ruthigen, Inc.), License and Supply Agreement (Oculus Innovative Sciences, Inc.), License and Supply Agreement (Ruthigen, Inc.)